Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...
Complex systems fascinate because of the way dynamic microscopic interactions give rise to striking, often unexpected macroscopic structures: convection cells in fluids, patterns in ecosystems, ...
Hosted on MSN
Merck & Co., Inc. (MRK) Partners with Variational AI to leverage AI in Enhancing Drug Development
Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in ...
“We are pleased to announce Merck as an early-access user of our Enki™ Platform,” said Handol Kim, CEO, Variational AI. “Merck will evaluate Enki’s ability to generate novel small molecules on targets ...
New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies VANCOUVER, British Columbia, February 20, 2025--(BUSINESS WIRE)--Variational AI, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results